GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nika Pharmaceuticals Inc (OTCPK:NIKA) » Definitions » Total Stockholders Equity

NIKA (Nika Pharmaceuticals) Total Stockholders Equity : $-0.21 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Nika Pharmaceuticals Total Stockholders Equity?

Nika Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-0.21 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nika Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $-0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nika Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.00.

Nika Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Nika Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nika Pharmaceuticals Total Stockholders Equity Chart

Nika Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
- -0.01 -0.02 -0.02 -0.08

Nika Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.08 -0.22 -0.25 -0.21

Nika Pharmaceuticals  (OTCPK:NIKA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nika Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-0.209-0.002)/1018.520
=-0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nika Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -0.209
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nika Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Nika Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nika Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nika Pharmaceuticals Inc (OTCPK:NIKA) » Definitions » Total Stockholders Equity
Comparable Companies
HROW BGM COLL PAHC EOLS TLRY PCRX ANIP AVDL KNSA ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
N/A
Address
2269 Merrimack Valley Avenue, Henderson, NV, USA, 89044
Website
https://www.nikapharmaceuticals.com
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution for the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.